Par Pharmaceutical Recalls Subpotent Gildess FE 1/20 Oral Contraceptive Tablets
Par Pharmaceutical is recalling Gildess FE 1/20 tablets because the ethinyl estradiol component is subpotent. The recall covers 822,009 tablets distributed nationwide and in Puerto Rico.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Par Pharmaceutical, Inc. is recalling Gildess FE 1/20 (norethindrone acetate, 1 mg and ethinyl estradiol tablets, 0.02 mg, USP and ferrous fumarate tablets, USP 75 mg), 28 count, 6 blisters (NDC 0603-7609-17). The recall is due to the ethinyl estradiol component being subpotent, meaning it contains less than the labeled amount of the active ingredient.
The affected product was manufactured in Canada by Patheon, Inc., for Qualitest Pharmaceuticals, USA. A total of 822,009 tablets are involved in this recall. The product was distributed nationwide and in Puerto Rico. Specific lot numbers are listed in the recall documentation.
Consumers with this product should stop using it and contact their healthcare provider for guidance. The FDA has classified this recall as Class III, indicating that use of or exposure to the product is not likely to cause adverse health consequences.
The recalled product
- Product
- Gildess FE 1/20 (norethindrone acetate, 1 mg and ethinyl estradiol tablets, 0.02 mg, USP and ferrous fumarate tablets, USP 75 mg), 28 count, 6 blisters (NDC 0603-7609-17), Rx only, Manufactured in Canada By: Patheon, Inc., Ontario, Canada L5N 7K9, Manufactured for QUALITEST PHAR
- Manufacturer
- Par Pharmaceutical, Inc.
- Category
- Drug — Oral Contraceptive
- Hazard
- Affected units
- 822,009
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot Numbers: 4101072
- 4101073
- 4101074
- 4149704
- 4152054
- 4152056
- 4152057
- 4159857
- 4169950
- 4169951
- 4187122
- 4187123
- 4187124
- 4187125
- 4190275
- 4190276
- 4190278
- 4190279
- 4265208
- 4265209
Distribution
Part of a larger recall action
This product is one of 5 recalled by Par Pharmaceutical, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · Par Pharmaceutical, Inc.
See all →- SeverePar Pharmaceutical Recalls BusPIRone Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2020-09-02
- SeverePar Pharmaceutical Recalls Glycopyrrolate Tablets Due to Unknown Impurity
FDA (Drugs) · 2020-04-08
- LowPar Pharmaceutical Recalls Prednisone Tablets Due to Incorrect Expiration Date
FDA (Drugs) · 2020-03-25
- LowPar Pharmaceutical Recalls Frovatriptan Tablets Due to Incorrect Expiration Date
FDA (Drugs) · 2020-02-19
- SeverePar Pharmaceutical Recalls Mycophenolate Mofetil Injection Due to Glass Fragment
FDA (Drugs) · 2019-05-15
Same hazard · subpotent drug
See all →- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02